ReviewClinical epigenetics2026
New perspective on epigenetic modification and immunotherapy in endometrial cancer.
Review in Clinical epigenetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Endometrial carcinoma (EC) is a heterogeneous gynecological malignancy. Epigenetic dysregulation promotes the initiation, progression, immune evasion, and therapeutic resistance of EC. Aberrant DNA methylation, histone methylation, histone acetylation, and chromatin remodeling affect key EC-associated pathways and help shape distinct molecular subtypes, including POLE-mutated and mismatch repair-deficient tumours. In this review, we summarize the major epigenetic alterations implicated in EC, with emphasis on DNA methylation regulators, histone-modifying enzymes, and emerging epigenetic targets such as DNMTs, HDACs, LSD1, EZH2, PRMTs, and BET proteins. We further highlight the rapidly evolving immunotherapy landscape in EC, including clinically established or practice-changing regimens such as pembrolizumab-, dostarlimab-, durvalumab-, and lenvatinib-based strategies, particularly in advanced or recurrent disease. In parallel, we discuss investigational epigenetic therapies, including DNMT inhibitors, HDAC inhibitors, LSD1 inhibitors, EZH2-targeted agents, PRMT inhibitors, and BRD4-directed approaches, which are being explored to restore tumour suppressor pathways, enhance tumour immunogenicity, and improve sensitivity to immune checkpoint blockade. By integrating EC-specific epigenetic mechanisms with current immunotherapy advances and ongoing combination strategies, this review provides a clinically oriented perspective on biomarker-guided precision treatment for EC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.